CONGRESSIONAL BUDGET OFFICE
Douglas W. Elmendorf, Director
U.S. Congress
Washington, DC 20515
August 28, 2009
Honorable Dave Camp
Ranking Member
Committee on Ways and Means
U.S. House of Representatives
Washington, DC 20515
Dear Congressman:
As you requested, the Congressional Budget Office (CBO) has estimated the
change in Medicare Part D premiums that would result from certain provisions
contained in title I in division B of H.R. 3200, Americafs Affordable Health
Choices Act of 2009, as introduced on July 14, 2009. According to CBOfs
estimates, enacting those changes would lead to an average increase in premiums
for Part D beneficiaries of about 5 percent in 2011, rising to about 20 percent in
2019. However, beneficiariesf spending on prescription drugs apart from those
premiums would fall, on average, as would their overall prescription drug
spending (including both premiums and cost sharing). As with CBOfs other
estimates related to this bill, the following analysis remains preliminary and does
not reflect any modifications or amendments made after July 14.
Under current law, the standard outpatient prescription drug benefit under Part D
of Medicare has the following features: an annual deductible for which the
beneficiary is responsible; a dollar range of coverage in which the beneficiary
pays 25 percent of the cost of covered drugs; and a catastrophic threshold above
which the beneficiary pays about 5 percent of the cost of covered drugs. In the
gap between the end of the initial coverage range and the catastrophic threshold.
commonly referred to as the doughnut hole.beneficiaries generally are liable for
all of their drug costs. For their Part D insurance coverage, most enrollees pay
premiums that finance about 25 percent of the cost of the coverage (on average);
the federal government pays the remaining 75 percent. For low-income
individuals, however, the federal government subsidizes a larger share of their
prescription drug costs, including their premiums and their spending in the
doughnut hole.
H.R. 3200 proposes several changes to the Medicare Part D program that would
affect federal spending:
. First, it would create a new rebate program that, under certain
circumstances, requires pharmaceutical manufacturers to pay the federal
government the difference between the statutory rebate under Medicaid
and the rebates paid to Medicarefs prescription drug plans. Specifically,
this policy would apply to covered drugs dispensed to full-benefit dual
eligible individuals.beneficiaries who are enrolled in both Medicare and
Medicaid. Because the statutory rebate provided under Medicaid is, on
average, larger than those negotiated by the plans providing the Medicare
drug benefit, this provision would reduce federal spending.1
. Second, it would phase out the doughnut hole by simultaneously
extending the benefitfs initial coverage limit and lowering the catastrophic
threshold at specified rates, resulting in the elimination of the doughnut
hole by 2022. This provision would increase federal spending because of
the additional coverage provided.
. Third, in the years before the doughnut hole was eliminated, the
legislation would require pharmaceutical manufacturers to provide to
beneficiaries who are not eligible for the low-income subsidy program a
50 percent discount on their spending in the doughnut hole for covered
brand-name drugs. Enrollees receiving those discounts would generally
increase their use of drugs somewhat and thus would be more likely to
exceed the drug benefitfs catastrophic threshold.2 The increased use of the
catastrophic part of the benefit would raise federal spending during the
years before the doughnut hole was eliminated, all else being equal.
According to CBOfs estimate, these provisions would collectively save the
federal government about $30 billion over the 2010.2019 period.3 CBO has not
estimated the impact of each provision separately because their effects are so
closely connected.
Under the proposal, beneficiariesf premiums would increase for two reasons.
First, with the doughnut hole phasing out and with more spending above the
catastrophic threshold, prescription drug plans would be responsible for covering
some costs in the doughnut hole and above the catastrophic level that they are not
required to cover under current law. Because enrollees pay for about 25 percent of
the cost of coverage through their premiums, premiums would also be higher. In
return for those higher premiums, enrollees would receive greater protection
against incurring high drug costs. As a result, beneficiariesf spending on
prescription drugs apart from the premiums would decrease, on average. That
reduction in cost sharing would outweigh the increase in premiums, again on
average, because of the subsidies provided by the federal government.so
beneficiariesf total prescription drug spending would fall on average. Of course,
the effect on total spending would vary among beneficiaries: Those who ended up
purchasing a relatively small amount of drugs in a year would pay more in
additional premiums than they would gain from lower cost sharing, while those
who purchased a relatively large amount of drugs in a year would gain more from
lower cost sharing than they would pay in higher premiums. CBO has not
estimated the number of beneficiaries who would fall into each of those groups.
Second, CBO expects that the responses of pharmaceutical manufacturers to those
three provisions of the legislation would also increase Part D premiums. Drug
manufacturers would be constrained from increasing prices for existing drugs but
could offset the rebates they would be required to pay for full-benefit dual eligible
individuals by charging higher prices for new drugs.particularly for
gbreakthroughh drugs (the first drugs that use new mechanisms to treat illnesses).
In addition, manufacturers would probably lower the rebates they pay to
prescription drug plans. Although they would continue to have an incentive to
provide rebates in exchange for having their products designated as gpreferredh
on the plansf formularies.which leads to higher volumes of sales.the rebates
would probably decline relative to their amounts under current law because the
benefit to the manufacturers of those added sales would be reduced by the new
discounts and rebates they would have to provide. Those responses would lead to
an increase in beneficiariesf premiums, CBO estimates, and they would also lead
to an increase in beneficiariesf payments for cost sharing.
Overall, CBO estimates that enacting the proposed changes would lead to an
average increase in premiums for Part D beneficiaries, above those under current
law, of about 5 percent in 2011. That effect would rise over time and reach about
20 percent in 2019. Beyond the 10-year budget window, the premiums would
increase slightly more until the doughnut hole was eliminated in 2022; beyond
that point, enrolleesf premiums would grow along with the cost for covered drugs.
As already noted, the proposed changes would also reduce beneficiariesf average
cost sharing and their average total drug spending. The net effect on drug
spending would differ among beneficiaries depending on the amount of their
purchases in a year.
I hope that you find this information useful. If you wish further details on this
analysis, CBO will be pleased to provide them. The staff contacts are Kate
Massey and Rebecca Yip.
Sincerely,
Douglas W. Elmendorf
Director
cc:
Honorable Charles B. Rangel
Chairman
Committee on Ways and Means
Honorable George Miller
Chairman
Committee on Education and Labor
Honorable John Kline
Senior Republican Member
Committee on Education and Labor
Honorable Henry A. Waxman
Chairman
Committee on Energy and Commerce
Honorable Joe Barton
Ranking Member
Committee on Energy and Commerce
1 For a discussion of the Medicaid rebate provisions, see Congressional Budget Office, Prices for
Brand-Name Drugs Under Selected Federal Programs (June 2005).
2 Beneficiaries who reached the doughnut hole also would be more likely to use brand-name drugs
than they are now under current law.
3 See Congressional Budget Office, gPreliminary Analysis of Americafs Affordable Health
Choices Act of 2009,h letter to the Honorable Charles B. Rangel (July 17, 2009).